Lymphoplasmacytic lymphoma primary prevention: Difference between revisions

	Lymphoplasmacytic lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Lymphoplasmacytic Lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Lymphoplasmacytic lymphoma primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lymphoplasmacytic lymphoma primary prevention
CDC on Lymphoplasmacytic lymphoma primary prevention
Lymphoplasmacytic lymphoma primary prevention in the news
Blogs on Lymphoplasmacytic lymphoma primary prevention
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Lymphoplasmacytic lymphoma primary prevention

Newer edit →

VisualWikitext

Revision as of 18:10, 12 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Primary Prevention

Primary prevention of Waldenström macroglobulinemia depends on the type of risk factor causing the disease.^[1]

Modifiable risk factors

Hepatitis C

Non-modifiable risk factors

Age > 50
Male gender
Race - White
Hereditary- Monoclonal gammopathy of undetermined significance

References

↑ Waldenström's macroglobulinemia. American Cancer Society. (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-prevention Accessed on November 11, 2015

Template:WH Template:WS

[PP-1] Waldenström's macroglobulinemia. American Cancer Society. (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-prevention Accessed on November 11, 2015

[1]

@@ Line 19: / Line 19: @@
 ==Primary Prevention==
-There are no established measures for the primary prevention of [disease name].
+Primary prevention of Waldenström macroglobulinemia depends on the type of risk factor causing the disease.<ref name="PP">Waldenström's macroglobulinemia. American Cancer Society. (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-prevention Accessed on November 11, 2015</ref>
+===Modifiable risk factors===
-OR
+*[[Hepatitis C]]
+===Non-modifiable risk factors===
-There are no available vaccines against [disease name].
+*Age > 50
+*Male gender
-OR
+*Race - White
+*Hereditary- [[Monoclonal gammopathy of undetermined significance]]
-Effective measures for the primary prevention of [disease name] include:
-*[Measure1]
-*[Measure2]
-*[Measure3]
-OR
-[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
-*[Strategy 1]
-*[Strategy 2]
-*[Strategy 3]
 ==References==